ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 885

Fatigue In SLE Is Associated With Upregulation Of Interferon- Alpha Related Gene Transcripts

Maureen A. McMahon1, Jennifer M. Grossman2, Bevra H. Hahn3, Lori Sahakian4, Isao Matsuura5, Elaine Lourenco6 and Brian Skaggs6, 1Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, 3Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 4Division of Rheumatology, Department of Medicine,, UCLA David Geffen School of Medicine, Los Angeles, CA, 5UCLA David Geffen School of Medicine, Los Angeles, CA, 6Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: fatigue and interferons, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Fatigue is a major complaint in at least 80% of SLE patients, and is often listed as the most disabling symptom of the disease; however, fatigue often does not improve significantly with standard treatments that reduce disease activity assessed by standard measures (SLEDAI).  Defining altered biologic pathways in SLE patients with severe fatigue might provide clues to disease pathways that have not been previously identified – or have been identified but not appreciated for their importance in SLE fatigue.  One possible pathway of interest is the IFNa pathway, well appreciated in SLE disease activity and recently identified as important in patients with chronic fatigue syndrome.  We hypothesized that gene expression studies comparing patients classified by high fatigue scores and low disease activity and patients with low fatigue scores/low disease activity might identify new or previously underappreciated pathways of SLE pathogenesis.

Methods:

We administered the Fatigue Severity Score (FSS) to a subset of SLE patients participating in a longitudinal SLE in atherosclerosis cohort study.  Monocyte RNA was isolated from peripheral blood of 5 SLE patients with severe fatigue (defined as ≥6 on FSS) and 8 SLE subjects with mild fatigue (≤ 4 on FSS), all of whom had low disease activity (SELENA-SLEDAI ≤ 4).  Whole genome transcript analysis was performed using Affymetrix Human U133+2.0 chips.  dChip software (Li lab, Harvard) was utilized to determine differentially expressed transcripts.  The Database from Annotation, Visualization, and Integrated Discovery (DAVID) program (http://david.abcc.ncifcrf.gov) was utilized to examine if any functional groups of genes were altered. To examine whether a subset of IFNa-regulated genes were dysregulated, differentially expressed genes were entered into the Web-based database www.interferome.org.  Differential transcript expression was confirmed by quantitative PCR.

Results:

The mean FSS score in the high fatigue group was 6.7 ± 0.5 vs. 2.8 ± 0.8 in the low fatigue group.  Approximately 300 transcripts were differentially expressed between the high and low fatigue groups (fold change ≥1.2 or ≤-1.2, p≤0.05). Three gene families were significantly altered in this comparison: the immune response gene category (Benjamini corrected p-value 3.8 e-8), regulation of apoptosis (2.5 e-6), and response to virus (2.8 e-3).  35% of the dysregulated transcripts were IFNa-regulated genes (expected ‘interferome’ transcripts would be ~8%), and most were upregulated in patients with high fatigue.  Dysregulation of five interferome genes was confirmed by qPCR analysis: ICAM1 (1.86-fold up, p=0.01), IRF1 (2.24-fold up, p=0.03), JAK2 (3.60-fold up, p=0.04), OAS-L (1.94-fold up, p<0.01), and TLR4 (2.63-fold up, p=0.01).

Conclusion:

Upregulation of IFNa-regulated transcripts, already known to associate with SLE disease activity, appear to also associate with high fatigue in patients with low SLEDAI.  Targeting IFNa pathways with specific therapeutic agents might be beneficial in patients suffering from fatigue, even in the absence of traditional high disease activity measurements.


Disclosure:

M. A. McMahon,

GlaxoSmithKline,

8;

J. M. Grossman,

UCB, Eli Lilly, Medimmune, pfizer- I am doing lupus clinical trials compounds made by these companies that are in phase 2 or 3 studies. I am an investigator in multcenter trials. ,

2;

B. H. Hahn,

Eli Lilly and Company,

5,

Biogen-IDEC,

5,

Astella Pharma ,

5,

Teva Pharmaceutical,

2;

L. Sahakian,
None;

I. Matsuura,
None;

E. Lourenco,
None;

B. Skaggs,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fatigue-in-sle-is-associated-with-upregulation-of-interferon-alpha-related-gene-transcripts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology